Latest Paracetamol Stories
ALLEGAN, Mich., Nov. 28, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle its Hatch-Waxman litigation relating to Ofirmev® (acetaminophen) injection brought by Cadence Pharmaceuticals, Inc. ("Cadence"). Under the terms of the settlement, Perrigo can launch a generic version of Ofirmev® (acetaminophen) injection on December 6, 2020, or earlier under certain circumstances. In addition, Perrigo has secured the right to be the sole...
SAN DIEGO, Nov. 28, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that it has entered into settlement and license agreements with Perrigo Company (Nasdaq: PRGO; TASE), and its subsidiary, Paddock Laboratories, LLC, to resolve pending patent litigation involving OFIRMEV® (acetaminophen) injection. The settlement agreement includes a stipulation by the parties requesting dismissal with prejudice of the lawsuit filed by Cadence in the U.S. District...
Lee Rannals for redOrbit.com – Your Universe Online Findings reported in the Journal of Allergy and Clinical Immunology showed babies that were given acetaminophen for pain and fever may have an increased risk of asthma symptoms. The Danish study included 336 children who were followed from birth to age seven. All of the children's mothers in the study had asthma, putting them at an increased risk for developing the lung disease. During the study, the children were assessed for...
ALLEGAN, Mich., Nov. 13, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle its Hatch-Waxman litigation relating to Acetadote® (acetylcysteine) injection brought by Cumberland Pharmaceuticals, Inc. ("Cumberland"). Under the terms of the settlement, Perrigo can launch a generic version of Acetadote® (acetylcysteine) injection upon expiration of the patents in May 2026. In addition, Perrigo entered into an agreement with Cumberland...
BOSTON, Nov. 12, 2012 /PRNewswire/ -- The misuse of acetaminophen is the leading cause of acute liver failure in the West. Informed patients and clearly labeled prescription bottles are necessary to avoid accidental overdoses. Patients with new prescriptions often are unaware of the presence of acetaminophen in their new drug nor do they recall their prescribers' advice concerning acetaminophen, according to researchers at Northwestern University who examined the behavior of 249...
SAN FRANCISCO, Nov. 12, 2012 /PRNewswire/ -- AstraZeneca today announced positive top-line results from two Phase III trials and one safety extension trial in patients with non-cancer related pain and opioid-induced constipation (OIC). These Phase III KODIAC trials evaluated the safety and efficacy of naloxegol, an oral peripherally-acting, mu-opioid receptor antagonist for the treatment of OIC, a common side effect of prescription opioids. KODIAC-04 and -05 are both multicenter,...
BOSTON, Nov. 10, 2012 /PRNewswire/ -- Among patients with acetaminophen-induced acute liver failure (ALF), bariatric surgery was 25 times more common than in the general population. Researchers at California Pacific Medical Center (CPMC) reported an alarming rate of bariatric surgery among patients with ALF from acetaminophen poisoning. They studied 101 patients with ALF between 2009 and 2011, of whom 54 had acetaminophen-induced ALF. Of those 54 patients 9 - or 16.7...
SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Ocera Therapeutics, Inc. announced that the first patient has enrolled in a Phase 2a study to evaluate the safety and tolerability of OCR-002 (ornithine phenylacetate) in the treatment of patients with acute liver injury (ALI) as well as those that have progressed to acute liver failure (ALF) following acetaminophen overdose. OCR-002 is an investigational drug designed to directly reduce circulating blood levels of ammonia which, at high...
NASHVILLE, Tenn., Nov. 7, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.(NASDAQ: CPIX) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for a second patent relating to its new formulation of Acetadote(® )(acetylcysteine) Injection, which is used to treat acetaminophen overdose. The original composition of matter patent covered the Acetadote formulation and was issued in April 2012. The new patent includes claims...
WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., Oct. 29, 2012 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the U.S. Food and Drug Administration (FDA) granted priority review to the New Drug Application (NDA) filed at the end of August 2012 for Stivarga(®) (regorafenib) tablets to treat patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with two...
